-- 根据周四提交给澳大利亚证券交易所的文件,Orica(ASX:ORI)启动了一项全公司范围的成本削减计划,目标是在未来三年内每年至少节省1亿澳元,同时继续将安全和增长作为优先事项。 文件还指出,该公司在上半财年因该计划产生了1090万澳元的净重组成本。预计该计划的大部分效益将从2027年开始显现。 受此消息影响,该公司股价在周四的交易中上涨了约7%。
Related Articles
ScinoPharm Taiwan Logs NT$16.5 Million Profit in Q1
ScinoPharm Taiwan (TPE:1789) posted a profit attributable to owners of NT$16.5 million, or NT$0.02 per share, in the first quarter of the year, according to a Wednesday Taiwan bourse filing.Shares slid over 2% in Thursday's midday trade.Operating revenue stood at NT$659.7 million, the pharmaceutical company said.The company did not provide comparative year-ago figures.
Kina Securities Lists Papua New Guinea's First Wholesale Corporate Bond
Kina Securities' (ASX:KSL) 235 million Papua New Guinean Kina, 10-year unsecured subordinated wholesale corporate bond was listed on PNGX Markets, the operator of Papua New Guinea's national stock exchange, on Wednesday, according to a Thursday Australian bourse filing.This represents Papua New Guinea's first listed wholesale corporate bond.The firm expects the issuance to support its balance sheet strength, capital management objectives, and the growth of its banking and financial services operations.Its shares rose 1% in recent trading on Thursday.
Home First Q4 Profit Soars to INR 1.5 Billion, Beats Estimates
Home First Finance Company India's (NSE:HOMEFIRST, BOM:543259) profit after tax rose to 1.49 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.05 billion rupees a year ago.Earnings per share came in at 14.22 rupees from 11.45 rupees a year ago, the financial services provider said in a filing to the Indian stock exchanges on Wednesday. The EPS was higher than the 14.08 rupees estimated by the analysts polled by Visible Alpha.Total revenue from operations also increased to 5.01 billion rupees from 2.15 billion rupees a year ago.The company's board recommended a dividend of 5.20 rupees per share of a face value of 2 rupees each for the financial year ended March 31.The company's shares were down 2% in recent trade.